Assessment of haemoglobin and serum markers of iron deficiency in people with cardiovascular disease

Graham, F. J., Friday, J. , Pellicori, P. , Greenlaw, N. and Cleland, J. G.F. (2023) Assessment of haemoglobin and serum markers of iron deficiency in people with cardiovascular disease. Heart, 109(17), pp. 1294-1301. (doi: 10.1136/heartjnl-2022-322145) (PMID:37130747)

[img] Text
296225.pdf - Published Version
Available under License Creative Commons Attribution.

2MB

Abstract

Background: The prevalence of anaemia and iron deficiency and their prognostic association with cardiovascular disease have rarely been explored at population level. Methods: National Health Service records of the Greater Glasgow region for patients aged ≥50 years with a broad range of cardiovascular diagnoses were obtained. During 2013/14, prevalent disease was identified and results of investigations collated. Anaemia was defined as haemoglobin <13 g/dL for men or <12 g/dL for women. Incident heart failure, cancer and death between 2015 and 2018 were identified. Results: The 2013/14 dataset comprised 197 152 patients, including 14 335 (7%) with heart failure. Most (78%) patients had haemoglobin measured, especially those with heart failure (90%). Of those tested, anaemia was common both in patients without (29%) and with heart failure (prevalent cases in 2013/14: 46%; incident cases during 2013/14: 57%). Ferritin was usually measured only when haemoglobin was markedly depressed; transferrin saturation (TSAT) even less often. Incidence rates for heart failure and cancer during 2015–18 were inversely related to nadir haemoglobin in 2013/14. A haemoglobin of 13–15 g/dL for women and 14–16 g/dL for men was associated with the lowest mortality. Low ferritin was associated with a better prognosis and low TSAT with a worse prognosis. Conclusion: In patients with a broad range of cardiovascular disorders, haemoglobin is often measured but, unless anaemia is severe, markers of iron deficiency are usually not. Low haemoglobin and TSAT, but not low ferritin, are associated with a worse prognosis. The nadir of risk occurs at haemoglobin 1–3 g/dL above the WHO definition of anaemia.

Item Type:Articles
Additional Information:P.P. and J.G.F.C. are supported by the British Heart Foundation Centre of Research Excellence (RE/18/6134217). P.P, F.G. and J.G.F.C. have been awarded a project grant from the British Heart Foundation to assess the prevalence of iron deficiency in patients undergoing elective cardiac surgery (PG/2019/35089). P.P. has received a research grant (Scotland Grant) from Heart Research UK (CS/15/1/31175).
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Friday, Dr Jocelyn and Graham, Dr Fraser and Greenlaw, Miss Nicola and Cleland, Professor John and Pellicori, Dr Pierpaolo
Authors: Graham, F. J., Friday, J., Pellicori, P., Greenlaw, N., and Cleland, J. G.F.
College/School:College of Medical Veterinary and Life Sciences > School of Cardiovascular & Metabolic Health
College of Medical Veterinary and Life Sciences > School of Health & Wellbeing > General Practice and Primary Care
College of Medical Veterinary and Life Sciences > School of Health & Wellbeing > Robertson Centre
Journal Name:Heart
Publisher:BMJ Publishing Group
ISSN:1355-6037
ISSN (Online):1468-201X
Published Online:02 May 2023
Copyright Holders:Copyright © 2023 The Authors
First Published:First published in Heart 109(17): 1294-1301
Publisher Policy:Reproduced under a Creative Commons License

University Staff: Request a correction | Enlighten Editors: Update this record

Project CodeAward NoProject NamePrincipal InvestigatorFunder's NameFunder RefLead Dept
172792Intravenous iron treatment in patients with heart failure and iron deficiency: a multicentre UK study (IRONMAN)Ian FordBritish Heart Foundation (BHF)CS/15/1/31175HW - Robertson Centre
303944BHF Centre of ExcellenceColin BerryBritish Heart Foundation (BHF)RE/18/6/34217CAMS - Cardiovascular Science